JPMorgan Chase & Co. started coverage on shares of CeriBell (NASDAQ:CBLL – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued an overweight rating and a $32.00 price objective on the stock.
A number of other equities analysts have also recently issued reports on CBLL. TD Cowen initiated coverage on CeriBell in a report on Tuesday. They issued a “buy” rating and a $31.00 price objective for the company. William Blair initiated coverage on CeriBell in a research note on Tuesday. They issued an “outperform” rating for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.00.
Get Our Latest Analysis on CBLL
CeriBell Stock Performance
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
- Five stocks we like better than CeriBell
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- AMD: The AI Disruptor – Is It Time to Follow Big Tech’s Lead?
- How to Use Stock Screeners to Find Stocks
- Analysts Signal Big Upside: Top 3 Stocks to Watch Right Now
- Profitably Trade Stocks at 52-Week Highs
- Bears Misjudged These 3 ETFs: Where Investors Can Find Upside
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
